Page last updated: 2024-11-04

17-octadecynoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

octadec-17-ynoic acid : An acetylenic fatty acid that is octadecanoi acid (stearic acid) which has been doubly dehydrogenated at positions 17 and 18 to give the corresponding alkynoic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1449
CHEMBL ID182310
CHEBI ID142447
SCHEMBL ID979048
MeSH IDM0135942

Synonyms (60)

Synonym
CBIOL_001996
l8wpg7cl86 ,
unii-l8wpg7cl86
tocris-0607
BIO1_001260
BIO2_000087
NCGC00024681-01
BIO1_000282
BIO2_000567
BIO1_000771
IDI1_033837
BSPBIO_001367
LMFA01030575
17-octadecynoic acid
17-octadecynoic acid, >=95% (gc)
NCGC00024681-03
NCGC00024681-02
KBIO3_000174
KBIOSS_000087
KBIO2_000087
KBIO2_002655
KBIO3_000173
KBIO2_005223
KBIOGR_000087
NCGC00024681-04
HMS1989E09
17-odya
34450-18-5
BML3-C04
HMS1361E09
HMS1791E09
CHEMBL182310
17-octadecyn-1-oic acid
octadec-17-ynoic acid
CHEBI:142447
gtpl8851
AKOS024458580
SCHEMBL979048
17-octadecynoicacid
DZIILFGADWDKMF-UHFFFAOYSA-N
HMS3402E09
HMS3649J09
mfcd00077382
alkynyl stearic acid
BP-23391
DTXSID50188024
sr-01000597622
SR-01000597622-1
J-019614
17-odya (17-octadecynoic acid)
FT-0752313
Q27070788
SR-01000597622-2
F82104
MS-23987
CS-0020696
HY-101016
R01-0053
PD020539
octadec-17-ynoicacid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The oral bioavailability of some drugs is markedly lower in cynomolgus monkeys than in humans."( Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.
Komuro, S; Mizuki, Y; Nishimuta, H; Sato, K; Yabuki, M, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" We compared cumulative CCK dose-response relationship in control cells and in cells where P450 had been induced by prior injection of animals with beta-naphthoflavone."( Pharmacological evaluation of the role of cytochrome P450 in intracellular calcium signalling in rat pancreatic acinar cells.
Bruce, JI; Elliott, AC, 2000
)
0.31
" A dose-response curve for each of the suicide inhibitors was developed."( Inhibition of cytochromes P450 and the hydroxylation of 4-monochlorobiphenyl in whole poplar.
Lehmler, HJ; Schnoor, JL; Zhai, G, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
P450 inhibitorAn enzyme inhibitor that interferes with the activity of cytochrome P450 involved in catalysis of organic substances.
EC 1.14.14.94 (leukotriene-B4 20-monooxygenase) inhibitorAny EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor that interferes with the action of leukotriene-B4 20-monooxygenase (EC 1.14.14.94).
EC 1.14.15.3 (alkane 1-monooxygenase) inhibitorAny EC 1.14.15.* (oxidoreductase acting on paired donors, with reduced Fe-S protein as one donor, incorporating 1 O atom) inhibitor that interferes with the action of alkane 1-monooxygenase (EC 1.14.15.3).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
long-chain fatty acidA fatty acid with a chain length ranging from C13 to C22.
acetylenic fatty acidAny unsaturated fatty acid containing at least one triple bond in the carbon chain framework.
terminal acetylenic compoundAn acetylenic compound which a carbon of the C#C moiety is attached to a hydrogen atom.
monounsaturated fatty acidAny fatty acid with one double or triple bond in the fatty acid chain and singly bonded carbon atoms in the rest of the chain. MUFAs have positive effects on the cardiovascular system, and in diabetes treatment.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.54810.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID893
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID504865
Microtubule-associated protein tauHomo sapiens (human)Potency17.63160.180013.557439.8107AID1460; AID1468
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.10000.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency19.95260.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency25.11890.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency11.22020.251215.843239.8107AID504327
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID883
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 4F2Homo sapiens (human)IC50 (µMol)5.00001.60004.26676.2000AID690542
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (21)

Processvia Protein(s)Taxonomy
very long-chain fatty acid metabolic processCytochrome P450 4F2Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 4F2Homo sapiens (human)
renal water homeostasisCytochrome P450 4F2Homo sapiens (human)
pressure natriuresisCytochrome P450 4F2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 4F2Homo sapiens (human)
leukotriene metabolic processCytochrome P450 4F2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 4F2Homo sapiens (human)
blood coagulationCytochrome P450 4F2Homo sapiens (human)
regulation of blood pressureCytochrome P450 4F2Homo sapiens (human)
fatty acid omega-oxidationCytochrome P450 4F2Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 4F2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 4F2Homo sapiens (human)
negative regulation of icosanoid secretionCytochrome P450 4F2Homo sapiens (human)
positive regulation of icosanoid secretionCytochrome P450 4F2Homo sapiens (human)
leukotriene B4 catabolic processCytochrome P450 4F2Homo sapiens (human)
vitamin E metabolic processCytochrome P450 4F2Homo sapiens (human)
menaquinone catabolic processCytochrome P450 4F2Homo sapiens (human)
phylloquinone catabolic processCytochrome P450 4F2Homo sapiens (human)
vitamin K catabolic processCytochrome P450 4F2Homo sapiens (human)
sodium ion homeostasisCytochrome P450 4F2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 4F2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 4F2Homo sapiens (human)
iron ion bindingCytochrome P450 4F2Homo sapiens (human)
protein bindingCytochrome P450 4F2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 4F2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 4F2Homo sapiens (human)
alkane 1-monooxygenase activityCytochrome P450 4F2Homo sapiens (human)
heme bindingCytochrome P450 4F2Homo sapiens (human)
leukotriene-B4 20-monooxygenase activityCytochrome P450 4F2Homo sapiens (human)
arachidonic acid omega-hydroxylase activityCytochrome P450 4F2Homo sapiens (human)
alpha-tocopherol omega-hydroxylase activityCytochrome P450 4F2Homo sapiens (human)
tocotrienol omega-hydroxylase activityCytochrome P450 4F2Homo sapiens (human)
aromatase activityCytochrome P450 4F2Homo sapiens (human)
20-hydroxy-leukotriene B4 omega oxidase activityCytochrome P450 4F2Homo sapiens (human)
20-aldehyde-leukotriene B4 20-monooxygenase activityCytochrome P450 4F2Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 4F2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 4F2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4F2Homo sapiens (human)
apical plasma membraneCytochrome P450 4F2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 4F2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID690542Inhibition of leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes by UV spectroscopy2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
2-Alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani.
AID242680Inhibitory activity against 20-Hydroxy-5,8,11,14-eicosatetraenoic acid synthase from arachidonic acid in rat renal microsome2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Design and synthesis of 1-(4-benzoylphenyl)imidazole derivatives as new potent 20-HETE synthase inhibitors.
AID1345195Human CYP4F2 (CYP4 family)1985The Journal of biological chemistry, Oct-25, Volume: 260, Issue:24
Leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes. Suicidal inactivation by acetylenic fatty acids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (99)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (2.02)18.7374
1990's33 (33.33)18.2507
2000's45 (45.45)29.6817
2010's16 (16.16)24.3611
2020's3 (3.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.84 (24.57)
Research Supply Index4.64 (2.92)
Research Growth Index5.92 (4.65)
Search Engine Demand Index29.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other103 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]